This content is only available within our institutional offering.
05 Aug 2024
Non material data changes
Sign in
This content is only available to commercial clients. Sign in if you have access or contact support@research-tree.com to set up a commercial account
This content is only available to commercial clients. Sign in if you have access or contact support@research-tree.com to set up a commercial account
Non material data changes
Ipsen (IPN:EPA), 0 | Ipsen SA (IPN:PAR), 0
- Published:
05 Aug 2024 -
Author:
Parkes Richard RP | Steventon Gary GS -
Pages:
9 -
We have adjusted our estimates for Ipsen''s 2Q and 1H 2024 results and its upgrade to guidance. In addition, we factor in an expected launch of new drug tovorafenib in 2026, with EUR100m of peak sales based on Ipsen''s ex US licensing deal with Day One Biopharmaceuticals. The net impact of these changes is to raise our sales and Core EPS forecasts by low single digits.
We do not consider the changes to be material; our rating is unchanged.